Sign inJoin waitlistJoin the waitlist

Locke Bryan

Program Director, Hematology / Oncology Fellowship · Medical College of Georgia

Credentials: · · · · ·

History

Hematology / Oncology Fellowship · Medical College of Georgia
Present
GCC Infusion Center · Medical College of Georgia
Present
Medical College of Georgia
Present

Hematology and Medical Oncology
University of Vermont Medical Center
2011–2014
Internal Medicine
University of Vermont Medical Center
2008–2011
University of Mississippi School of Medicine
2004–2008

Research

Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides
Virology · 2004 · 157 citations
Identification of a cDNA encoding channel catfish interferon
Developmental & Comparative Immunology · 2004 · 88 citations
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated…
JAMA Oncology · 2023 · First of 15 authors · 59 citations

Gang Zhou
5 papers · 1 as a fellow
Anand Jillella
4 papers
Leo Gordon
4 papers
Vamsi Kota
4 papers
Mark Dalgetty
3 papers · 3 as a fellow
Natasha Savage
3 papers
SL
Scott Long
3 papers
Amany Keruakous
2 papers
Chandini Kannan
2 papers · 2 as a resident
David Munn
2 papers
Jorge Cortes
2 papers
Sruthi Dontu
2 papers

Clinical trials

Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy
Principal investigator · Completed
Augusta University
2019–2024
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2038